| Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts. |
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Michaelson Jennifer | See Remarks | Nov 25 | Option Exercise | 4.30 | 4,000 | 17,200 | 57,031 | Nov 29 04:05 PM | | Michaelson Jennifer | See Remarks | Nov 25 | Sale | 13.30 | 4,000 | 53,200 | 53,031 | Nov 29 04:05 PM | | Michaelson Jennifer | See Remarks | Sep 27 | Option Exercise | 4.30 | 4,000 | 17,200 | 57,031 | Sep 29 04:05 PM | | Michaelson Jennifer | See Remarks | Sep 27 | Sale | 12.40 | 4,000 | 49,600 | 53,031 | Sep 29 04:05 PM | | F2 Vision SCS | 10% Owner | Aug 04 | Sale | 14.31 | 25,989 | 371,788 | 1,255,963 | Aug 04 09:01 PM | | F2 Vision SCS | 10% Owner | Aug 03 | Sale | 14.24 | 19,129 | 272,334 | 1,281,952 | Aug 04 09:01 PM | | F2 Vision SCS | 10% Owner | Aug 02 | Sale | 14.10 | 4,792 | 67,554 | 1,301,081 | Aug 04 09:01 PM | | Michaelson Jennifer | Chief Development Officer | Jul 25 | Option Exercise | 4.30 | 8,000 | 34,400 | 61,031 | Jul 26 05:44 PM | | Michaelson Jennifer | Chief Development Officer | Jul 25 | Sale | 14.51 | 8,000 | 116,080 | 53,031 | Jul 26 05:44 PM | | Savill Corrine | Acting Chief Business Officer | Jul 19 | Sale | 15.22 | 14,958 | 227,661 | 149,615 | Jul 21 04:30 PM | | Savill Corrine | Acting Chief Business Officer | Jul 18 | Sale | 15.06 | 5,042 | 75,933 | 164,573 | Jul 21 04:30 PM | | Savill Corrine | Acting Chief Business Officer | Jul 11 | Sale | 13.33 | 40,000 | 533,304 | 169,615 | Jul 12 04:14 PM | | Jovan-Embiricos Morana | 10% Owner | Jun 24 | Option Exercise | 4.30 | 140,374 | 603,608 | 252,881 | Jun 28 09:24 PM | | F2 Bioscience I 2017 Ltd | 10% Owner | Jun 23 | Sale | 13.00 | 29,631 | 385,310 | 537,392 | Jun 23 06:47 PM | | F2 Bioscience I 2017 Ltd | 10% Owner | Jun 22 | Sale | 12.70 | 49,953 | 634,578 | 567,023 | Jun 23 06:47 PM | | F2 Bioscience I 2017 Ltd | 10% Owner | Jun 21 | Sale | 12.77 | 22,319 | 284,929 | 616,976 | Jun 23 06:47 PM | | AHMED NADIM | President and CEO | Jun 06 | Buy | 12.40 | 8,090 | 100,316 | 8,090 | Jun 07 04:33 PM | | BVF PARTNERS L P/IL | 10% Owner | Jun 01 | Buy | 11.00 | 751,396 | 8,264,905 | 4,058,854 | Jun 03 06:24 PM | | F2 Vision SCS | 10% Owner | May 16 | Sale | 11.23 | 35,158 | 394,828 | 1,305,873 | May 16 08:54 PM | | BVF PARTNERS L P/IL | 10% Owner | May 13 | Buy | 9.13 | 109,900 | 1,003,936 | 3,653,213 | May 16 07:34 PM | | F2 Vision SCS | 10% Owner | May 13 | Sale | 10.11 | 119,508 | 1,208,377 | 1,341,031 | May 16 08:54 PM | | BVF PARTNERS L P/IL | 10% Owner | May 12 | Buy | 9.06 | 1,000,000 | 9,060,000 | 3,599,615 | May 16 07:34 PM | | F2 Vision SCS | 10% Owner | May 12 | Sale | 9.25 | 264,072 | 2,442,587 | 1,460,539 | May 16 08:54 PM | | BVF PARTNERS L P/IL | 10% Owner | Apr 01 | Buy | 10.75 | 276,000 | 2,966,972 | 3,056,616 | Apr 05 06:45 PM |
|
